Acumen Pharmaceuticals Begins Phase 2 Trial and Updates Finances
Company Announcements

Acumen Pharmaceuticals Begins Phase 2 Trial and Updates Finances

Acumen Pharmaceuticals (ABOS) has issued an update.

Acumen Pharma has updated its corporate presentation, now available on its website, to reflect the commencement of their Phase 2 trial for sabirnetug and the latest financial standing as of the end of March 2024. This update is part of their ongoing communications strategy and is not considered legally filed information but is provided to comply with market regulations.

For an in-depth examination of ABOS stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAcumen appoints Schacterle as Chief Regulatory Officer, Head of Quality
TheFlyAcumen presents data on pTau217 assay to screen for Phase 2 ALTITUDE-AD trial
TheFlyAcumen to deliver late-breaking presentation on ACU193 at CTAD conference
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App